Alzheimer's Disease and Ashwaganda

Reference: Ghattacharya SK, Kumar A & Ghosal S: Effects of glycowithanolides from Withania somnifera on an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 9:110-13, 1995.

Summary: Rats injected with ibotenic acid (IA) develop a syndrome with pathological features similar to Alzheimer's disease, particularly destruction of cholinergic neurons in the central nervous system. In this study, rats given IA alone were compared to those given an aqueous and chloroform extract of Withania somnifera (ashwaganda) along with IA. All rats developed memory deficits and decay in cholinergic levels and function. Those receiving high dose ashwaganda extract (50 mg/kg body weight), however, had a significantly lower deterioration in all areas measured at fourteen days than those given IA alone. Low dose ashwaganda extract (20 mg/kg body weight) had no significant effect. The authors conclude that the high dose extract of ashwaganda apparently can protect central cholinergic systems and deserves further study in the treatment of Alzheimer's disease.

Natural Product Research Consultants, Inc.

Share this with your friends